Pharmacodynamics and Tolerance of Nicotinamide Mononucleotide (NMN, 400mg/Day) in Healthy Adults
Condition(s):Healthy VolunteersLast Updated:January 26, 2023Completed
Hide Studies Not Open or Pending
Condition(s):Healthy VolunteersLast Updated:January 26, 2023Completed
Condition(s):Chronic Lymphocytic LeukemiaLast Updated:February 12, 2024Recruiting
Condition(s):MenopauseLast Updated:November 18, 2021Completed
Condition(s):AgingLast Updated:October 1, 2021Completed
Condition(s):SARS-CoV-2 Infection; Acute Kidney InjuryLast Updated:December 26, 2023Completed
Condition(s):COVID-19Last Updated:November 8, 2022Completed
Condition(s):Ischemia Reperfusion Injury; Myocardial Injury; Acute Kidney InjuryLast Updated:July 18, 2023Recruiting
Condition(s):Neuralgia; MyalgiaLast Updated:April 20, 2021Completed
Condition(s):Delirium Confusional StateLast Updated:January 26, 2021Unknown status
Condition(s):Sarcopenia; Nicotinamide Adenine Dinucleotide Concentration; Muscle Quality and NAD+ ContentLast Updated:October 26, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.